Literature DB >> 21205250

Feasibility and safety of intravenous thrombolysis for acute ischaemic stroke in northern Greece.

Jobst Rudolf, Georgios Tsivgoulis, Georgia Deretzi, Ioannis Heliopoulos, Konstantinos Vadikolias, Iakovos Tsiptsios, Charitomeni Piperidou.   

Abstract

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21205250     DOI: 10.1111/j.1747-4949.2010.00547.x

Source DB:  PubMed          Journal:  Int J Stroke        ISSN: 1747-4930            Impact factor:   5.266


× No keyword cloud information.
  4 in total

Review 1.  The chain of care enabling tPA treatment in acute ischemic stroke: a comprehensive review of organisational models.

Authors:  Maarten M H Lahr; Gert-Jan Luijckx; Patrick C A J Vroomen; Durk-Jouke van der Zee; Erik Buskens
Journal:  J Neurol       Date:  2012-08-23       Impact factor: 4.849

2.  Intravenous recombinant tissue plasminogen activator for acute ischemic stroke: a feasibility and safety study.

Authors:  Elyar Sadeghi-Hokmabadi; Mehdi Farhoudi; Aliakbar Taheraghdam; Mazyar Hashemilar; Daryous Savadi-Osguei; Reza Rikhtegar; Kaveh Mehrvar; Ehsan Sharifipour; Parisa Youhanaee; Reshad Mirnour
Journal:  Int J Gen Med       Date:  2016-10-25

Review 3.  Current perspectives on the use of intravenous recombinant tissue plasminogen activator (tPA) for treatment of acute ischemic stroke.

Authors:  Sherita N Chapman; Prachi Mehndiratta; Michelle C Johansen; Timothy L McMurry; Karen C Johnston; Andrew M Southerland
Journal:  Vasc Health Risk Manag       Date:  2014-02-24

4.  Intravenous thrombolysis for acute ischemic stroke in Greece: the Safe Implementation of Thrombolysis in Stroke registry 15-year experience.

Authors:  Georgios Tsivgoulis; Odysseas Kargiotis; Jobst Rudolf; Apostolos Komnos; Antonios Tavernarakis; Theodoros Karapanayiotides; John Ellul; Aristeidis H Katsanos; Sotirios Giannopoulos; Maria Gryllia; Apostolos Safouris; Panagiotis Papamichalis; Konstantinos Vadikolias; Panayiotis Mitsias; Georgios Hadjigeorgiou
Journal:  Ther Adv Neurol Disord       Date:  2018-06-28       Impact factor: 6.570

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.